TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31042813

Group type: EXPERIMENTAL
Intervention: Length-for-age z-score (LAZ) at birth
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: ΔLAZ from 6 to 18 months
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 18 months
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: ΔLAZ during 0-6 months
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: ΔLAZ from 18 months to 4-6 years
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 6 months
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) at 4-6 years
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Motor and social-emotional development
Number of subjects: 710
Study: 29596014

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT) for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no training, CON)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 50
Study: 26056119

Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg weekly + placebo-IV every four weeks
Number of subjects: 1262

Group type: COMPARATOR
Intervention: TCZ-IV 8 mg/kg every four weeks + placebo-SC weekly
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: TCZ-SC
Number of subjects: 1262

Group type: COMPARATOR
Intervention: TCZ-IV
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Patients who switched formulations
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1262
Study: 24834511

Group type: EXPERIMENTAL
Intervention: Pramipexole extended release (ER)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Pramipexole immediate release (IR)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Pramipexole ER
Number of subjects: 1055
Study: 23342783

Group type: EXPERIMENTAL
Intervention: Umbilicus moxibustion therapy plus Jingui Shenqi Pill (8 pills, 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Jingui Shenqi Pill (8 pills, 3 times a day)
Number of subjects: 60
Study: 20177405

Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing second-generation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-generation trials
Number of subjects: 0
Study: 18548965

Group type: EXPERIMENTAL
Intervention: Procera AllCeram (PA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experimental hot-pressed ceramic (EC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metal-ceramic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All systems
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metal-ceramic and experimental systems
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enamel opposing metal-ceramic and experimental crowns
Number of subjects: 48
Study: 16043683

Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 5 to 40 mg/d
Number of subjects: 12557
Study: 11377599

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², day 1) and cisplatin (80 mg/m², day 2)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Gemcitabine (1100 mg/m², days 1 and 8) and docetaxel (100 mg/m², day 8)
Number of subjects: 441
Study: 9203010

Group type: EXPERIMENTAL
Intervention: Visual flash stimuli
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Auditory non‐target oddball stimuli (P3 experiment)
Number of subjects: 10
Study: 7968075

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation (inpatient for 8 weeks and outpatient for 16 weeks)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Number of subjects: 89
Study: 2886143

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 4
Study: 2529776

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic hormone (ANH) infusion at 0.47 pmol.kg‐1.min‐1 for 2.5 hours
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 7
Study: 31729189

Group type: EXPERIMENTAL
Intervention: baricitinib
Number of subjects: 740
Study: 31669188

Group type: EXPERIMENTAL
Intervention: PA and diet intervention
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: PA only intervention
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Diet only intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard care (1 visit)
Number of subjects: 149
Study: 28011387

Group type: EXPERIMENTAL
Intervention: Immediate intensive non-surgical periodontal treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rescue treatment with delayed intensive treatment
Number of subjects: 46
Study: 25195169

Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg, maximum 100 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 17
Study: 22310483

Group type: EXPERIMENTAL
Intervention: Relational Coordination
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Relational Coordination and Reciprocal Learning
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Reciprocal Learning
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Electronic Medical Record presence
Number of subjects: 283
Study: 21507295

Group type: EXPERIMENTAL
Intervention: TNF‐α treatment (1.0 ng/mL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated FS group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TNF‐α treatment
Number of subjects: 16
Study: 19128956

Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection (APR)
Number of subjects: 0
Study: 17105853

Group type: EXPERIMENTAL
Intervention: 25 mg etanercept (ETN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg etanercept (ETN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: etanercept (ETN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study: 15629872

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reboxetine 8 mg/day
Number of subjects: 35
Study: 11163781

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone, olanzapine, quetiapine)
Number of subjects: 9
Study: 9778755

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rimantadine
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 100
Study: 7880555

Group type: EXPERIMENTAL
Intervention: Standard mailed reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed reminder plus incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phoned reminder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mailed reminder on physician's letterhead
Number of subjects: 0

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 0
Study: 3206383

Group type: EXPERIMENTAL
Intervention: Peptide histidine valine (2.5-10 pmol kg-1 min-1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study: 30653856

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (280 mL/d for 8 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (acute and chronic)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 28223259

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AED) administered from 4 days before surgery until 1 month after surgery
Number of subjects: 320
Study: 25060406

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray (100 to 1600 mcg) during a 26-day open-label titration period
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Number of subjects: 130
Study: 23098672

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 22082789

Group type: EXPERIMENTAL
Intervention: Cystocele plication during transvaginal repair
Number of subjects: 22

Group type: COMPARATOR
Intervention: No cystocele plication during transvaginal repair
Number of subjects: 22
Study: 19934866

Group type: EXPERIMENTAL
Intervention: Milrinone (phosphodiesterase 3 inhibitor)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 34
Study: 16546596

Group type: EXPERIMENTAL
Intervention: Opioid blockade with naltrexone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naltrexone administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Infrequent tanner control
Number of subjects: 16
Study: 14977243

Group type: EXPERIMENTAL
Intervention: Listening to Mozart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Listening to Beethoven
Number of subjects: 0
Study: 11262198

Group type: EXPERIMENTAL
Intervention: canarypox-CMV pp65
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 9253563

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger with electret filters (HMEF)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No filtering device
Number of subjects: 250
Study: 8305334

Group type: COMPARATOR
Intervention: Limited field radiotherapy (LF group)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Wide field radiotherapy (WF group)
Number of subjects: 708
Study: 3505192

Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)D3 + Ca 1.0 g/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1 alpha (OH)D3 1.0 microgram/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ca 1.0 g/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 61
Study: 30198326

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium supplementation (1.25×10^10 cfu each of Bifidobacterium longum subsp. longum BB536, B. longum subsp. infantis M‐63, Bifidobacterium breve M‐16V and B. breve B‐3)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium supplementation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 26808580

Group type: EXPERIMENTAL
Intervention: Psychoanalytic-Interactional Therapy (PIT)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Expert Psychodynamic Therapy (E-PDT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control condition (treatment as usual/waiting for treatment)
Number of subjects: 168
Study: 24586994

Group type: EXPERIMENTAL
Intervention: 10 mg of rosuvastatin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22750188

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) self‐help volume
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 236
Study: 20404000

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 0
Study: 17885799

Group type: EXPERIMENTAL
Intervention: Maximum voltage-guided technique (MVGT) for CTI ablation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete anatomical ablation line
Number of subjects: 20
Study: 16094549

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Inpatients' relatives
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Day hospital patients' relatives
Number of subjects: 95
Study: 12427413

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Statin-naive control group
Number of subjects: 50
Study: 10205101

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.25 ml (1:1000)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 7543659

Group type: EXPERIMENTAL
Intervention: Craniectomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 37
Study: 2198826

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 328549

Group type: EXPERIMENTAL
Intervention: Pyrithioxine
Number of subjects: 44
Study: 30626341

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program with cognitive training (dual-task training)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Multicomponent exercise program alone
Number of subjects: 188
Study: 27121921

Group type: EXPERIMENTAL
Intervention: iPad presentation of physiotherapy information
Number of subjects: 42

Group type: COMPARATOR
Intervention: Paper booklet presentation of physiotherapy information
Number of subjects: 42
Study: 26349919

Group type: EXPERIMENTAL
Intervention: Sugar-reduced foods and beverages for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular sugar foods and beverages for 8 weeks
Number of subjects: 50
Study: 24681586

Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22669708

Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instrumented lumbar fusion
Number of subjects: 0
Study: 20643915

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 889
Study: 18356605

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 0
Study: 16206598

Group type: EXPERIMENTAL
Intervention: Combination of bisoprolol and analapril with trimetazidine (70 mg/day for 6 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combination of bisoprolol and analapril
Number of subjects: 75
Study: 14607719

Group type: EXPERIMENTAL
Intervention: Dynamic MRI
Number of subjects: 53

Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 53
Study: 10432966

Group type: EXPERIMENTAL
Intervention: Fosfo‐soda fleet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method (X‐prep)
Number of subjects: 40
Study: 8527283

Group type: EXPERIMENTAL
Intervention: TRH 0.5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TRH 1.0 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RX77368 1 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 1730831

Group type: EXPERIMENTAL
Intervention: Bronchial provocation test with alpha-amylase
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nasal provocation with alpha-amylase
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral provocation with alpha-amylase
Number of subjects: 83

Group type: COMPARATOR
Intervention: Specific IgE values
Number of subjects: 83
Study: 6714795

Group type: EXPERIMENTAL
Intervention: 5 micrograms ceruletide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 micrograms ceruletide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 micrograms ceruletide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31557679

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed fingolimod (switched from placebo or IFN β‐1a)
Number of subjects: 0
Study: 29243805

Group type: EXPERIMENTAL
Intervention: Interactive media
Number of subjects: 310

Group type: COMPARATOR
Intervention: Silent nature video
Number of subjects: 310

Group type: COMPARATOR
Intervention: Media-free comparison
Number of subjects: 310
Study: 27154462

Group type: EXPERIMENTAL
Intervention: MedSentry remote medication monitoring system
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study: 24768553

Group type: EXPERIMENTAL
Intervention: European School Fruit campaign (treated group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (supermarkets outside 500 m radius of schools)
Number of subjects: 0
Study: 24056905

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia (protocol H)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Euglycemic normoinsulinemia (protocol N)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Flicker stimulation
Number of subjects: 7
Study: 21419298

Group type: EXPERIMENTAL
Intervention: White ProRoot MTA (WMTA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EndoSequence Root Repair Material (ES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcium hydroxide (POS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (NEG)
Number of subjects: 24
Study: 19724055

Group type: EXPERIMENTAL
Intervention: Deferasirox (35 mg/kg single dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (adequate response)
Number of subjects: 15
Study: 17710426

Group type: EXPERIMENTAL
Intervention: Isotretinoin for the first 10 days of each month for 6 months (group 1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isotretinoin daily for the first month, then first 10 days of each month for 5 months (group 2)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isotretinoin daily for 6 months (group 3)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison between group 1 and group 3
Number of subjects: 66

Group type: COMPARATOR
Intervention: Groups 1 and 2
Number of subjects: 66
Study: 15339234

Group type: EXPERIMENTAL
Intervention: Phonemic perception training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (listened to computerized books)
Number of subjects: 34
Study: 11495074

Group type: EXPERIMENTAL
Intervention: 60 mg of lansoprazole once daily for 5 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 9778202

Group type: EXPERIMENTAL
Intervention: ACE-I treatment
Number of subjects: 1016

Group type: COMPARATOR
Intervention: No ACE-I treatment
Number of subjects: 1016
Study: 7759929

Group type: EXPERIMENTAL
Intervention: Thoracic outlet syndrome (TOS) patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 2407872

Group type: EXPERIMENTAL
Intervention: Diltiazem SR monotherapy
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide monotherapy
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Combination therapy (Diltiazem SR + Hydrochlorothiazide)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 7404480

Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bovine heparin and Porcine heparin
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serial blood samples from thrombocytopenic patients
Number of subjects: 43
Study: 31810848

Group type: EXPERIMENTAL
Intervention: L-PRF
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 29649082

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 0
Study: 28521248

Group type: EXPERIMENTAL
Intervention: Blood transfusion serious game
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 25405577

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 673
Study: 23950921

Group type: EXPERIMENTAL
Intervention: Real-time strategy (RTS) game emphasizing maintenance and rapid switching between multiple information and action sources
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21883648

Group type: EXPERIMENTAL
Intervention: Pure chromated glycerin (CG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Chromated glycerin mixed with one‐third lidocaine‐epinephrine 1% (CGX)
Number of subjects: 102
Study: 19794979

Group type: EXPERIMENTAL
Intervention: C1 inhibitor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conventional risk factors (age, gender, hypertension, BMI)
Number of subjects: 100
Study: 17916468

Group type: EXPERIMENTAL
Intervention: RF-based plasma microtenotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arthroscopic subacromial decompression
Number of subjects: 60
Study: 14970894

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (therapeutic exercises, especially Bobath method) starting on average 15 days after stroke
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (similar pharmacological treatments)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 11216977

Group type: EXPERIMENTAL
Intervention: D/P (diltiazem and propranolol)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: F (flecainide)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: COMPARATOR
Intervention: Emergency room assistance
Number of subjects: 37
Study: 9645278

Group type: EXPERIMENTAL
Intervention: (+)‐tramadol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: (‐)‐tramadol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Racemate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7524280

Group type: EXPERIMENTAL
Intervention: Open adenectomy (OA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 55
Study: 2075850

Group type: EXPERIMENTAL
Intervention: Imagery scripts with negative affect and explicit smoking urges
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imagery scripts with negative affect alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imagery scripts with positive affect alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imagery scripts with neutral affect alone
Number of subjects: 60
Study: 378580

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium suspension
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo suspension
Number of subjects: 21
Study: 31338807

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (non-stimulus group)
Number of subjects: 106
Study: 27808555

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Benfothiamine (control)
Number of subjects: 122